On March 25, Beijing Tongrentang Co.Ltd(600085) disclosed the annual report of 2021. According to the announcement, in 2021, Beijing Tongrentang Co.Ltd(600085) achieved an operating revenue of 14.603 billion yuan, a year-on-year increase of 13.86%; The net profit attributable to the shareholders of the listed company was 1.227 billion yuan, a year-on-year increase of 19.00%, the net cash flow from operating activities was 3.426 billion yuan, a year-on-year increase of 57.56%, and the comprehensive gross profit margin was 47.62%, a year-on-year increase of 0.58 percentage points.
“At present, the development of traditional Chinese medicine has ushered in a historic opportunity” Beijing Tongrentang Co.Ltd(600085) disclosed announcement shows that the report of the 19th National Congress of the Communist Party of China clearly stated that “we should pay equal attention to traditional Chinese and Western medicine, inherit and develop the cause of traditional Chinese medicine”, and incorporate the development of traditional Chinese medicine into the strategy of “healthy China”.
The announcement shows that in February 2021, the general office of the State Council issued the notice on several policies and measures to accelerate the development of traditional Chinese medicine, which provides a policy basis for accelerating the solution of prominent problems faced in the development of traditional Chinese medicine and better realizing the inheritance and innovation of traditional Chinese medicine; With the modernization of traditional Chinese medicine becoming a national strategy, the internationalization of traditional Chinese medicine continues to be included in relevant national plans. In the outline of the strategic plan for the development of traditional Chinese medicine (20162030), it is clearly proposed to strengthen the foreign exchange and cooperation of traditional Chinese medicine and expand the international trade of traditional Chinese medicine; China’s 2030 China health plan one belt, one road plan, is also required to build a cooperative mode based on the bilateral cooperation mechanism and promote the health cooperation between China and the countries along the belt. The industry expects that with the help of policies, the prospect of traditional Chinese medicine industry in overseas markets will be more and more considerable in the future.
Beijing Tongrentang Co.Ltd(600085) also stressed that the development of traditional Chinese medicine is still facing severe challenges. The covid-19 pneumonia epidemic has accelerated the adjustment of the international pattern, and the international environment is becoming more and more complex. The Beijing Tongrentang Co.Ltd(600085) “going global” strategy will face more challenges; As the China Meheco Group Co.Ltd(600056) market has shifted from the seller’s market to the buyer’s market, the market competition in the traditional Chinese medicine industry will become more intense, the differentiation, integration and reorganization of traditional Chinese medicine enterprises will further intensify, and the business pressure faced by the company will become more prominent; With the promulgation and implementation of the new pharmacopoeia and the successive introduction of industrial regulatory measures, higher requirements will be put forward for the company’s product quality, cost control, business model and high-quality development. “The company will accelerate the pace of industrial transformation and upgrading, promote quality change, efficiency change and power change, cultivate opportunities in the crisis and open a new situation in the changing situation” Beijing Tongrentang Co.Ltd(600085) pointed out.
